Johnson & Johnson vs Kymera Therapeutics, Inc.
JNJ vs KYMR — side-by-side comparison from reported financials. JNJ leads 6, KYMR leads 2 of 8 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Kymera Therapeutics, Inc.
KYMR · Healthcare
$112.40+2.84%Strong
| Metric | JNJ | KYMR |
|---|---|---|
| Price | $261.79 | $112.40 |
| Market cap | $631B | $9.35B |
| Revenue (TTM) | $97.9B | $105M |
| Revenue growth | +5.6% | -5.8% |
| Net margin | 21.5% | -285.3% |
| Free cash flow | $22.2B | -$238M |
| Net cash (debt) | ($27.8B) | $766M |
| 1-year price return | +37.0% | +97.1% |
| P/E | 29.9 | — |
| P/E vs own history (cheap-side %) | 16% | — |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | -22% |
| Altman Z-score | — | 47.67 |
| CV checks passed | 10 of 11 | 4 of 11 |
| Employees | 140,800 | 273 |
Full résumé-style profiles: JNJ CV · KYMR CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.